These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 19361301)

  • 21. [Update on the pharmacological interactions of systemic antifungal agents].
    Viudes A; Pemán J; Cantón E; Ubeda P; Gobernado M
    Rev Esp Quimioter; 1999 Jun; 12(2):107-15. PubMed ID: 10562670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Present problems and future trend of antifungals for deep seated mycosis. Azole antifungal agents].
    Niki Y; Nakajima M; Matsushima T
    Nihon Ishinkin Gakkai Zasshi; 1999; 40(3):163-8. PubMed ID: 10423511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.
    Saad AH; DePestel DD; Carver PL
    Pharmacotherapy; 2006 Dec; 26(12):1730-44. PubMed ID: 17125435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know.
    Leather HL
    Bone Marrow Transplant; 2004 Jan; 33(2):137-52. PubMed ID: 14676788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacology of azoles].
    Azanza JR; García-Quetglas E; Sádaba B
    Rev Iberoam Micol; 2007 Sep; 24(3):223-7. PubMed ID: 17874860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders.
    Worth LJ; Blyth CC; Booth DL; Kong DC; Marriott D; Cassumbhoy M; Ray J; Slavin MA; Wilkes JR
    Intern Med J; 2008 Jun; 38(6b):521-37. PubMed ID: 18588523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel, Rapid, and Low-Volume Assay for Therapeutic Drug Monitoring of Posaconazole and Other Long-Chain Azole-Class Antifungal Drugs.
    Wiedman GR; Zhao Y; Perlin DS
    mSphere; 2018 Dec; 3(6):. PubMed ID: 30567902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives.
    Yao M; Srinivas NR
    Biomed Chromatogr; 2009 Jul; 23(7):677-91. PubMed ID: 19309762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics of voriconazole.
    Levêque D; Nivoix Y; Jehl F; Herbrecht R
    Int J Antimicrob Agents; 2006 Apr; 27(4):274-84. PubMed ID: 16563707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic antifungal agents. Drug interactions of clinical significance.
    Albengres E; Le Louët H; Tillement JP
    Drug Saf; 1998 Feb; 18(2):83-97. PubMed ID: 9512916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.
    Lakhani P; Patil A; Majumdar S
    J Ocul Pharmacol Ther; 2019; 35(1):6-22. PubMed ID: 30481082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of drug-drug interactions with systemic azole antifungals.
    Bates DW; Yu DT
    Drugs Today (Barc); 2003 Oct; 39(10):801-13. PubMed ID: 14668935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of flavonoids with azole drugs for fungal infections: key pharmacokinetic challenges.
    Srinivas NR
    Future Microbiol; 2019 Jun; 14():733-738. PubMed ID: 31271062
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug interactions during therapy with three major groups of antimicrobial agents.
    Shakeri-Nejad K; Stahlmann R
    Expert Opin Pharmacother; 2006 Apr; 7(6):639-51. PubMed ID: 16556082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of voriconazole in the treatment of central nervous system blastomycosis.
    Ta M; Flowers SA; Rogers PD
    Ann Pharmacother; 2009 Oct; 43(10):1696-700. PubMed ID: 19724015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic drug monitoring of voriconazole.
    Brüggemann RJ; Donnelly JP; Aarnoutse RE; Warris A; Blijlevens NM; Mouton JW; Verweij PE; Burger DM
    Ther Drug Monit; 2008 Aug; 30(4):403-11. PubMed ID: 18641555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro interactions between azoles and amiodarone against clinical Candida albicans.
    Guo Q; Sun S; Li Y; Yu J; Shi C
    Int J Antimicrob Agents; 2008 Jan; 31(1):88-90. PubMed ID: 18006280
    [No Abstract]   [Full Text] [Related]  

  • 38. The evolution of azole compounds in antifungal chemotherapy.
    Borgers M
    J Chemother; 1989 Jul; 1(4 Suppl):238-40. PubMed ID: 16312384
    [No Abstract]   [Full Text] [Related]  

  • 39. Azole-resistant central nervous system aspergillosis.
    van der Linden JW; Jansen RR; Bresters D; Visser CE; Geerlings SE; Kuijper EJ; Melchers WJ; Verweij PE
    Clin Infect Dis; 2009 Apr; 48(8):1111-3. PubMed ID: 19272019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifungal Drugs TDM: Trends and Update.
    Kably B; Launay M; Derobertmasure A; Lefeuvre S; Dannaoui E; Billaud EM
    Ther Drug Monit; 2022 Feb; 44(1):166-197. PubMed ID: 34923544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.